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Irofulven (6-hydroxymethylacylfulvene, HMAF, MGI
114) is one of a new class of anticancer agents that are
semisynthetic derivatives of the mushroom toxin illudin
S. Preclinical studies and clinical trials have demon-
strated that irofulven is effective against several tumor
types. Mechanisms of action studies indicate that iroful-
ven induces DNA damage, MAPK activation, and apopto-
sis. In this study we found that in ovarian cancer cells,
CHK2 kinase is activated by irofulven while CHK1 ki-
nase is not activated even when treated at higher con-
centrations of the drug. By using GM00847 human fibro-
blast expressing tetracycline-controlled, FLAG-tagged
kinase-dead ATR (ATR.kd), it was demonstrated that
ATR kinase does not play a major role in irofulven-
induced CHK2 activation. Results from human fibro-
blasts proficient or deficient in ATM function (GM00637
and GM05849) indicated that CHK2 activation by iroful-
ven is mediated by the upstream ATM kinase. Phospho-
rylation of ATM on Ser1981, which is critical for kinase
activation, was observed in ovarian cancer cell lines
treated with irofulven. RNA interference results con-
firmed that CHK2 activation was inhibited after intro-
ducing siRNA for ATM. Finally, experiments done with
human colon cancer cell line HCT116 and its isogenic
CHK2 knockout derivative; and experiments done by
expressing kinase-dead CHK2 in an ovarian cancer cell
line demonstrated that CHK2 activation contributes to
irofulven-induced S phase arrest. In addition, it was
shown that NBS1, SMC1, and p53 were phosphorylated
in an ATM-dependent manner, and p53 phosphorylation
on serine 20 is dependent on CHK2 after irofulven treat-
ment. In summary, we found that the anticancer agent,
irofulven, activates the ATM-CHK2 DNA damage-signal-
ing pathway, and CHK2 activation contributes to S
phase cell cycle arrest induced by irofulven.
Irofulven1 (6-hydroxymethylacylfulvene, HMAF, MGI 114) is
one of a new class of anticancer agents that are analogs of
mushroom-derived illudin toxins. Preclinical studies and clin-
ical trials have demonstrated that irofulven is effective against
several tumor types (1–17). Studies of mechanisms of irofulven
action suggest that it induces DNA damage, MAP kinase acti-
vation and apoptosis (18–20). It is also suggested that iroful-
ven-elicited DNA lesions are mainly repaired by transcription-
coupled nucleotide excision repair (TC-NER) (21).
In response to DNA damage, the cell evokes signal transduc-
tion pathways to arrest at G1/S, S, or G2/M checkpoints, allow-
ing time to deal with the insult (22, 23). It has been well
documented that DNA damage activates ATM (ataxia telangi-
ectasia-mutated), and/or ATR (ATM-RAD3-related) kinases,
two apical protein kinases of the DNA damage response path-
ways. ATM and ATR phosphorylate downstream effector ki-
nases, CHK1 and CHK2. It is generally believed that ATM is
the kinase mainly responding to ionizing radiation (IR)-in-
duced DNA double strand breaks, while ATR responds to the
formation of DNA adducts and stalled replication induced by
UV, genotoxic drugs, and radiation (23–29).
ATM phosphorylates NBS1 on Ser343 and activates its func-
tion in forming the MRE11-RAD50-NBS1 complex and S phase
checkpoint control (30–32). ATM phosphorylates SMC1 on
Ser957 and Ser966. Activated SMC1 plays a critical role in S
phase checkpoint control and radiosensitivity (33, 34). ATM
also phosphorylates MDM2 on Ser395, indirectly regulating p53
activity (35). Both ATM and CHK2 phosphorylate BRCA1 (36–
38). BRCA1 plays an important role in S and G2/M checkpoint
control (39–41).
ATM phosphorylates CHK2 on Thr68 leading to CHK2 ki-
nase activation (42–46), while both ATM and ATR phosphoryl-
ate CHK1 on Ser317 and Ser345 resulting in its activation (29,
47–49). ATM and ATR phosphorylate p53 on Ser15 (23, 50–53),
and CHK1 and CHK2 phosphorylate p53 on Ser20 (54–59),
leading to its accumulation and activation. Activation of p53
initiates cell cycle arrest- and DNA repair-related genes such
as p21, GADD45, and 14-3-3 and leads to G1 and G2 arrest (22,
23, 54–56, 60, 61). Activation of p53 also regulates the expres-
sion of a plethora of apoptosis-related genes resulting in p53-
dependent apoptosis (62–64). Activation of CHK1 and CHK2
also regulates S phase by phosphorylating CDC25A (65–72), or
the G2/M transition by phosphorylating CDC25C (29, 42, 68,
71, 73–76). However, controversy exists regarding the role of
CHK2 in cell cycle regulation and p53 phosphorylation. Recent
studies indicate that CHK2 is dispensable in radiation-induced
G1 and G2/M arrest, and CHK1 and CHK2 are unlikely to be
the regulators of p53 (77–79). It has also been shown that cells
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from CHK2 knockout mice have normal S phase and G2/M
transition (56, 57).
In this study, we found that the anticancer agent, irofulven,
activates ATM-CHK2 DNA damage-signaling pathway, and
activates NBS1, SMC1, and p53 in an ATM-dependent manner.
Irofulven also induces CHK2-dependent p53 phosphorylation
on Ser20. This CHK2 activation contributes to irofulven-in-
duced S phase arrest.
EXPERIMENTAL PROCEDURES
Cell Culture—All cell lines were maintained in various media sup-
plemented with 10% fetal bovine serum in a 37 °C incubator with 5%
CO2 atmosphere. Human ovarian cancer cell lines A2780, A2780/CP70,
CAOV3, OVCAR3, and SKOV3 were cultured in RPMI1640. Human
colon cancer cell line HCT116 and its isogenic CHK2 knockout deriva-
tive HCT116 CHK2/ (78) (generously provided by Prof. Bert Vo-
gelstein, Johns Hopkins University, Baltimore, MD) were cultured in
McCoy’s 5A medium. The SV40-transformed human normal fibroblast
GM00637, the AT (ataxia telangiectasia) fibroblast GM05849 and its
parental non-transformed AT fibroblast GM05823 (Coriell Institute,
Camden, NJ) were grown in DMEM. The ATM-complemented AT fibro-
blast (AT22IJE-T-pEBS7-YZ5, generously provided by Prof. Yosef Shi-
loh, Tel Aviv University, Israel) (80) was grown in Dulbecco’s modified
Eagle’s medium with 100 g/ml hygromycin (Invitrogen, Carlsbad, CA).
GM00847 human fibroblast-expressing tetracycline-controlled, FLAG-
tagged kinase-dead ATR (ATR.kd) (81) (generously provided by Drs.
Stuart L. Schreiber and Shlomo Handeli of the Fred Hutchinson Cancer
Research Center, Seattle, WA) was grown in DMEM supplemented
with 400 g/ml of G418 (Invitrogen). For ATR.kd induction, cells were
treated with 1.5 g/ml of doxycycline (Sigma) for 48 h. For UV treat-
ment in control experiments, cells were treated with 50 J/m2 of UV light
in Stratalinker 2400 (Stratagene, La Jolla, CA) followed by one addi-
tional hour of incubation. To inhibit CDC25A degradation, proteasome
inhibitor LLnL (N-Acetyl-Leu-Leu-Norleu-al) (Sigma) (50 M) were
added to cells 30 min before irofulven treatment.
Colonogenic Survival Assay—The IC50 concentration of irofulven in
ovarian cancer cell lines and the colon cancer cell line HCT116 was
determined by colonogenic survival assay. Cells were plated in 6-well
plates overnight in complete medium. Cells were treated with different
concentrations of irofulven for 1 h. Medium was then replaced with
fresh drug-free medium and incubated for 7–10 days. Colonies were
stained with PBS containing 0.04% crystal violet and 0.5% paraform-
aldehyde for about 10 min. Staining liquid was aspirated and colonies
counted.
Western Blotting—Western blot was performed as described previ-
ously (20). Briefly, cell lysates were prepared in cold immunoprecipita-
tion buffer (10 mM Tris, pH 7.4, 1% Triton X-100, 0.5% Nonidet P-40,
150 mM NaCl, 30 mM sodium fluoride, 40 mM -glycerophosphate, 20
mM sodium pyrophosphate, 1 mM EDTA, 1 mM EGTA, and 0.2 mM
phenylmethylsulfonyl fluoride). Total cellular protein (40 g) was elec-
trophoresed in SDS-PAGE gels and transferred to Immobilon-P mem-
branes (Millipore, Bedford, MA). Western blot protein detection was
performed using the ECL kit (Amersham Biosciences) according to the
manufacturer’s recommendations. Monoclonal antibodies against actin
and FLAG were purchased from Sigma. Monoclonal antibody against
PARP and polyclonal antibodies against ATR, SMC1, NBS1, CDC25A,
p53, and phosphorylated p53 on Ser15 were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Polyclonal antibodies against phos-
phorylated CHK1 on Ser345, phosphorylated CHK2 on Thr68, phospho-
rylated p53 on Ser20, CHK1 and CHK2 were purchased from Cell
Signaling Technology (Beverly, MA). Polyclonal antibody against phos-
phorylated ATM on Ser1981 was purchased from Rockland Immuno-
chemicals (Gilbertsville, PA). Polyclonal antibody for ATM was pur-
chased from Oncogene Research Products (San Diego, CA). Polyclonal
antibodies against phosphorylated NBS1 on Ser343 and phosphorylated
SMC1 on Ser957 were purchased from Novus Biologicals (Littleton, CO).
BrdU Pulse Labeling and Flow Cytometry—Cells were prelabeled
with 10 M BrdU (Roche Applied Science, Indianapolis, IN) for 1 h
before treatment with irofulven for 1 h. After drug removal, cells were
incubated in drug-free medium and harvested by trypsinization at
different time points. Cells were washed once with cold PBS and fixed
in 75% ethanol/PBS. Cells were then washed with 1% BSA/PBS and
resuspended in 2 N HCl/0.5% Triton X-100. After incubating for 30 min
at room temperature, the cells were washed twice with 1% BSA/PBS
and resuspended in 0.2 ml of 1% BSA/PBS. Anti-BrdU antibody (20 l)
(BD PharMingen, San Diego, CA) was added to each cell suspension.
After incubating in the dark for 30 min at room temperature, cells were
centrifuged and resuspended in PBS containing 10 g/ml propidium
iodide, 20 g/ml RNase A, 0.1% sodium citrate, and 0.1% Triton X-100.
Cells were analyzed by FACSCalibur (BD Biosciences). Cell cycle dis-
tributions among BrdU-positive cells were analyzed by ModFit v3.0
software (Verity, Topsham, ME).
RNA Interference—The sense and antisense oligonucleotides for
small interfering RNA (siRNA) were synthesized and annealed by
Dharmacon (Lafayette, CO). The sequences of two double-stranded
siRNAs for ATM are CATCTAGATCGGCATTCAG and TGGTGCTATT-
TACGGAGCT. The siRNA sequence for bacterial green fluorescence
protein (GFP) gene is TGGAAGCGTTCAACTAGCA. A2780 cells were
transfected twice within a 24-h period starting at 40% confluence with
100 nM final concentrations of siRNAs for ATM (two ATM siRNAs were
pooled) and GFP using Oligofectamine (Invitrogen) according to the
manufacturer’s recommendations. Twenty-four hours after transfec-
tion, cells were treated with irofulven for 1 h, washed, and incubated in
drug-free media, and harvested 12 h later. Cell lysates were prepared
for Western blot as described above.
Transfection of Kinase-dead CHK2 and Flow Cytometry—Ovarian
cancer cell line CAOV3 was transfected twice within a 24-h period with
vector or HA-tagged kinase-dead CHK2 (82) (generously provided by
Dr. Jann Sarkaria of the Mayo Clinic and Foundation, Rochester, MN)
using FuGENE 6 (Roche Applied Science, Indianapolis, IN) according to
the manufacturer’s recommendations. Forty-eight hours after transfec-
tion, cells were treated with irofulven for 1 h, washed, and incubated in
drug-free media, and harvested 12 h later. Cells were then washed with
PBS and fixed in 70% ethanol. After washing twice with PBS, cells were
permeabilized with 0.25% Triton X-100 in PBS on ice for 15 min, then
washed with 1% BSA/PBS, and the cell pellet was suspended in 100 l
of 1% BSA/PBS containing 1 g of FITC-conjugated anti-HA antibody
(Roche Applied Science) for 3 h at room temperature. Cells were washed
three times in PBS and then resuspended in PBS containing 10 g/ml
of propidium iodide and 20 g/ml of RNase A. Cells were analyzed by
FACSCalibur (BD Biosciences), and cell cycle distributions for pro-
pidium iodide and FITC-positive cells were analyzed by ModFit v3.0
software (Verity, Topsham, ME).
RESULTS
Irofulven Activates CHK2 Kinase in Ovarian Cancer
Cells—To assess irofulven cytotoxicity, ovarian cancer cell lines
were treated with different concentrations of irofulven for 1 h,
then the drug was removed, and colonogenic formation assays
were performed. The IC50 concentrations obtained for ovarian
cancer cell lines (A2780, A2780/CP70, CAOV3, SKOV3, and
OVCAR3) ranged from 0.7 to 2.3 M.
In response to DNA damage, CHK2 kinase is phosphorylated
at Thr68, which is critical for CHK2 activation (42–44, 46, 83).
To investigate the DNA damage response pathway that might
be activated by irofulven-induced DNA damage, ovarian cancer
cells were treated with the 1 IC50 concentration of irofulven
for 1 h, and incubated for 24 h after drug treatment. Western
blot assay was performed with antibody recognizing the phos-
phorylated form of CHK2 on Thr68. As indicated in Fig. 1A,
CHK2 kinase was activated by irofulven in all ovarian cancer
cell lines. The activation of CHK2 kinase by irofulven was time
and dose-dependent (Fig. 1, B and C).
CHK1 Kinase Is Not Activated by Irofulven—Because CHK1
kinase primarily responds to UV and drug-induced DNA dam-
age (23–29), it was critical to test whether CHK1 was activated
by irofulven-induced DNA damage. Western blot assay was
performed with antibody recognizing phosphorylated CHK1 on
Ser345. As shown in Fig. 2, CHK1 was not activated by iroful-
ven in all four cell lines tested, even when cells were treated
with 3 IC50 concentrations, a treatment resulting in 90%
cell killing. A2780 treated with 50 J/m2 of UV light served as
positive control for antibody against phosphorylated CHK1
(Fig. 2).
Next, we examined whether CHK1 was activated in the
absence of CHK2 expression. Isogenic human colon cancer cell
line HCT116 and its CHK2 knockout derivative (78) were
treated with 1 IC50 concentration of irofulven for 1 h followed
Irofulven Activates CHK2 via ATM 39585
by an additional 12- or 24-h incubation in drug-free media.
Western blot analyses were performed with antibodies against
phosphorylated CHK1 on Ser345, CHK1, CHK2, and actin. As
shown in Fig. 3A, CHK1 phosphorylation was not detected in
CHK2/ or CHK2/ cells. A2780 treated with 50 J/m2 of
UV light served as positive control for CHK1 activation. The
Western blot for CHK2 confirmed that CHK2 expression is
absent in CHK2/ cells (Fig. 3A). Further, to demonstrate
that the CHK1 activation pathway is intact in these cells,
parental HCT116 (CHK2/) cells were treated with 50 J/m2
of UV light, and Western blot results indicated that the path-
way leading to CHK1 phosphorylation is indeed intact (Fig.
3B). This is consistent with the finding that CHK1 can be
activated when these cells were treated with ionizing radiation
(78).
CHK2 Activation by Irofulven Is Not Mediated by ATR—Both
ATM and ATR have been reported to activate CHK2 in re-
sponse to DNA damage (28, 42–46, 84, 85). To determine the
possible involvement of ATR in irofulven-induced CHK2 acti-
vation, GM00847 human fibroblasts expressing tetracycline-
controlled, FLAG-tagged kinase-dead ATR (ATR.kd) (81) were
used. Both doxycycline-induced and un-induced cells were
treated with irofulven. As shown in Fig. 4A, the FLAG-tagged,
kinase-dead ATR was strongly induced by 1.5 g/ml of doxycy-
cline for 48 h as determined by Western blot with anti-FLAG
antibody. However, under the same conditions, CHK2 activa-
tion by irofulven (8 M, 1 h treatment followed by 12 h of
incubation) was apparent. There actually was some increase of
phosphorylated CHK2 in cells expressing kinase-dead ATR
after irofulven treatment (Fig. 4A). To confirm that the doxy-
cycline-induced kinase-dead ATR was functional, the doxycy-
cline-treated and untreated cells were exposed to 50 J/m2 of UV
light. As shown in Fig. 4B, CHK1 kinase was strongly activated
by UV in un-induced cells, but the induced kinase-dead ATR
greatly blocked CHK1 activation by UV irradiation, indicating
that ATR.kd was functional.
CHK2 Activation by Irofulven Is Dependent on ATM—To
determine the role that ATM might play in irofulven-induced
CHK2 activation, Western blot assay was carried out with
cellular extracts from ATM-deficient and proficient cell lines
treated with irofulven. As shown in Fig. 5A, CHK2 was acti-
vated by irofulven in a concentration-dependent manner in the
SV40-transformed normal human fibroblast GM00637. In con-
trast, under the same irofulven treatment conditions, CHK2
was not activated in SV40-transformed human AT (ataxia tel-
angiectasia) fibroblast, GM05849, and its parental non-trans-
formed AT fibroblast, GM05823, which are known to be defi-
cient in ATM function (Fig. 5B). As a positive control, the
CHK2 activation was observed in the ATM-complemented AT
fibroblast (AT22IJE-T-pEBS7-YZ5) (80) (Fig. 5B). Taken to-
gether, these results indicate that the CHK2 activation by
irofulven is dependent on the ATM status.
DNA damage induces rapid autophosphorylation of ATM on
serine 1981. This ATM autophosphorylation causes dimer dis-
sociation and initiates ATM kinase activity (86). To further
study the involvement of ATM kinase activation in irofulven-
induced CHK2 activation, A2780 and CAOV3 ovarian cancer
cells were treated with irofulven for 1 h followed by 24 h of
FIG. 1. CHK2 activation by irofulven in ovarian cancer cell
lines. Antibody recognizing the phosphorylated form of CHK2 kinase
on Thr68 was used to determine the activated CHK2. Blots for CHK2
and actin served as loading control. A, cells were treated with 1 IC50
concentration of irofulven for 1 h followed by additional 24 h of incu-
bation. B, cells were treated as above followed by different incubation
time. C, cells were treated with 1 or 3 IC50 concentration of irofulven
for 1 h followed by additional 24 h of incubation.
FIG. 2. CHK1 is not activated by irofulven. Ovarian cancer cell
lines were treated with 1 or 3 IC50 concentration of irofulven for 1 h
followed by additional 24 h of incubation. Western blot was performed
with antibody recognizing phosphorylated CHK1 on Ser345. Extracts
from UV (50 J/m2)-treated A2780 cells were loaded as positive control
for CHK1 activation. Blots for CHK1 and actin served as loading
control.
FIG. 3. CHK1 is not activated by irofulven in the absence of
CHK2 expression. A, human colon cancer cell line HCT116 and its
CHK2 knockout derivative were treated with 1 IC50 concentration of
irofulven for 1 h followed by an additional 12 or 24 h of incubation.
CHK1 activation was observed by Western blot with antibody recogniz-
ing the phosphorylated form of CHK1 on Ser345. Western blots for
CHK1 and actin served as loading control. The blot for CHK2 indicated
the CHK2 status in parental and CHK2 knockout cells. A2780 treated
with 50 J/m2 of UV light served as positive control for antibody against
phosphorylated CHK1 on Ser345. B, parental HCT116 (CHK2/) cells
were treated with 50 J/m2 of UV light, CHK1 activation was determined
by Western blot with anti-phospho-CHK1 antibody, and the blots for
CHK1 and actin were shown as the loading control.
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drug-free incubation. Western blot assay was carried out with
an antibody specifically recognizing the phosphorylated ATM
on Ser1981. As shown in Fig. 6A, irofulven treatment resulted in
ATM kinase phosphorylation on Ser1981 in both A2780 and
CAOV3 cell lines.
To further confirm the role that ATM played in CHK2 acti-
vation in ovarian cancer cells following irofulven treatment,
The RNA interference experiment was performed in A2780
cells. As shown in Fig. 6B, ATM protein level was greatly
reduced by transfection of siRNA against ATM (siATM), but
not by transfection of siRNA against bacterial green fluores-
cence protein (siGFP). Accordingly, CHK2 activation following
irofulven treatment was greatly attenuated in cells transfected
with siATM (Fig. 6B).
ATM and CHK2 Target Proteins Activated by Irofulven—In
response to ionizing radiation, ATM phosphorylates NBS1 on
Ser343 (30–32), SMC1 on Ser957 and Ser966 (33, 34), p53 on
Ser15 (52, 53, 87, 88). ATM and CHK2 phosphorylate BRCA1 on
multiple serine sites (36–38). CHK2 phosphorylates p53 on
Ser20 and stabilizes p53 (54, 56, 59, 89).
In an effort to further understand irofulven-induced activa-
tion of ATM and CHK2, the activation of ATM and CHK2
target proteins was tested. Ovarian cancer cell lines A2780,
CAOV3, SKOV3, and OVCAR3 were treated with irofulven,
Western blot results demonstrated that NBS1 was phosphoryl-
ated on Ser343 in SKOV3 and OVCAR3 cells, but not in A2780
and CAOV3 cells as determined with antibody recognizing
phosphorylated NBS1. When the NBS1 protein expression lev-
els were compared, it was shown that much less NBS1 was
expressed in A2780 and CAOV3 cells than in SKOV3 and
OVCAR3 cells (Fig. 7A). Further, Western blot results also
demonstrated that SMC1 was phosphorylated in CAOV3,
SKOV3 and OVCAR3 cells as determined by antibody recog-
nizing phosphorylated SMC1 on Ser957. Phosphorylation of p53
on Ser15 was observed in A2780 cells harboring wild-type p53
(90) (Fig. 7A). In the three other cell lines, p53 is known to be
mutated (91).
To determine the dependence of NBS1, SMC1, and p53 acti-
vation on ATM after irofulven treatment, normal human fibro-
blast GM00637 and AT fibroblast GM05849 were treated with
irofulven and Western blot results indicated that more NBS1
was phosphorylated on Ser343 and band-shifted in ATM wild-
type GM00637 cells than in AT cells, GM05849. Similarly,
more SMC1 phosphorylation on Ser957 and p53 phosphoryla-
tion on Ser15 were observed in ATM wild-type cells than in AT
cells (Fig. 7B).
In summary, NBS1, SMC1, and p53 were activated by irof-
ulven both in ovarian cancer cell lines and in normal human
fibroblasts, and this activation is dependent on ATM.
CHK2 phosphorylates p53 on Ser20 and this phosphorylation
event stabilizes the p53 protein (54–56, 59, 68). However, re-
cent studies suggest that it is unlikely that CHK2 regulates
p53 (78, 79). To determine whether irofulven-induced CHK2
FIG. 4. The role of ATR in CHK2 activation by irofulven.
GM00847 human fibroblast expressing tetracycline-controlled, FLAG-
tagged kinase-dead ATR (ATR.kd) was induced with 1.5 g/ml of doxy-
cycline for 48 h. The induced and un-induced cells were then treated
with 8 M of irofulven for 1 h followed by 12 h of post-treatment
incubation. A, ATR.kd induction was shown on the top panel by West-
ern blot with anti-FLAG antibody. The nonspecific band (n.s.) was
shown as the loading control for FLAG-ATR.kd induction. CHK2 acti-
vation was shown by Western blot with anti-phospho-CHK2 antibody
on the bottom panel. The blot for CHK2 was shown as the loading
control. B, induced and un-induced GM00847-ATR.kd cells were treated
with 50 J/m2 of UV light. CHK1 activation was determined by Western
blot with anti-phospho-CHK1 antibody; the blot for CHK1 was shown
as the loading control.
FIG. 5. The role of ATM in CHK2 activation by irofulven. A,
SV40-transformed human normal fibroblast GM00637 was treated with
different concentrations of irofulven as indicated for 1 h followed by 24 h
of drug-free incubation. CHK2 activation was determined by Western
blot with anti-phospho-CHK2 antibody. Western blots for CHK2 and
actin were shown as the loading control. B, SV40-transformed human
AT (ataxia telangiectasia) fibroblast, GM05849, its parental non-trans-
formed AT fibroblast, GM05823, and the ATM-complemented AT fibro-
blast (AT22IJE-T-pEBS7-YZ5) were treated with irofulven. The CHK2
activation was determined by Western blot with anti-phospho-CHK2
antibody, the nonspecific band (n.s.) was shown as the loading control.
FIG. 6. ATM is phosphorylated following irofulven treatment
in ovarian cancer cells and inhibition of ATM expression blocks
irofulven-induced CHK2 activation. A, ovarian cancer cell lines
A2780 and CAOV3 were treated with their respective 1 IC50 concen-
tration of irofulven for 1 h followed by 24 h of drug-free incubation. The
phosphorylation of ATM kinase on Ser1981 was determined by Western
blot with anti-phospho-Ser1981-ATM antibody. B, A2780 cells were
transfected with small interfering RNAs for GFP (siGFP) and ATM
(siATM) as described under “Experimental Procedures.” ATM protein
level and CHK2 activation were determined by Western blot with
anti-ATM and anti-phospho-CHK2 antibodies. Western blots for CHK2
and actin were used as the loading control.
Irofulven Activates CHK2 via ATM 39587
activation has any effect on p53 phosphorylation on Ser20,
antibody recognizing phosphorylated p53 on Ser20 was used in
Western blot analysis. In A2780 (wild-type p53) and CAOV3
(mutated p53) cells after irofulven treatment, p53 phosphoryl-
ation and protein accumulation were observed (Fig. 7C). To
assess whether p53 phosphorylation on Ser20 is dependent on
CHK2, the human colon cancer cell line HCT116 and its CHK2
knockout derivative (78) were treated with irofulven and West-
ern blot results indicated that increased phosphorylation of p53
on Ser20, and greater p53 protein accumulation were observed
in parental HCT116 cells compared with CHK2 knockout cells,
suggesting this phosphorylation event is dependent on CHK2
status (Fig. 7D).
BRCA1 phosphorylation was also determined by Western
blot in HCT116 cells and its CHK2 knockout cells treated with
irofulven, but no difference on BRCA1 phosphorylation was
observed (data not shown).
Taken together, in response to irofulven-induced DNA dam-
age, p53 was phosphorylated on serine 20 in a CHK2-depend-
ent manner.
CHK2 Activation by Irofulven Contributes to S Phase Ar-
rest—Many studies have linked CHK2 activation to G1, S or
G2/M phase arrest, respectively (42, 54–56, 65–67, 73, 74). To
understand the possible role that irofulven-induced CHK2 ac-
tivation might play in cell cycle arrest, we examined the iso-
genic human colon cancer cell line HCT116 and its CHK2
knockout derivative (78) after irofulven treatment. These
paired cell lines were treated with 1 IC50 concentration of
irofulven for 1 h followed by additional 12 or 24 h of incubation
in drug-free media. Western blot analysis indicated that CHK2
was only expressed and activated in parental HCT116
(CHK2/) cells (Fig. 8A). To determine the effect of CHK2
activation on cell cycle arrest, the CHK2/ and CHK2/
cells were pulse-labeled with BrdU before drug treatment, har-
vested at different time points and stained with FITC-conju-
gated anti-BrdU antibody and propidium iodide. FACS analy-
sis for BrdU-positive cells indicated that at time zero, in the
untreated control groups, there were 84% of CHK2/ cells in
S phase compared with 75% of CHK2/ cells in S phase.
Three hours after the drug treatment, there were 4-fold more
CHK2/ cells arrested at S phase than CHK/ cells. This
trend was maintained throughout the 24-h period after drug
removal (Fig. 8B). Similarly, when comparing the S phase ratio
of irofulven-treated over untreated in each cell line, it was
clearly shown that there were more cells arrested at S phase in
CHK2/ cells than in CHK/ cells (Fig. 8C).
In response to IR-induced DNA damage, ATM and CHK2
phosphorylate CDC25A on serine 123, leading to its ubiquiti-
nation and degradation, and consequently resulting in S phase
arrest (65, 66). To further confirm the results obtained with
CHK2 knockout cell lines, the ovarian cancer cell line CAOV3
was first treated with irofulven and CDC25A protein level was
determined by Western blot. 12 h after irofulven treatment,
CDC25A was degraded. Addition of the proteasome inhibitor,
LLnL, could block this degradation, indicating cells were ar-
rested at S phase at this time point (Fig. 9A). To further study
the role that CHK2 activation plays in irofulven-induced S
phase arrest, CAOV3 cells were transfected with vector or
HA-tagged kinase-dead CHK2 (CHK2.kd) (82). Cells were then
treated with irofulven and stained with FITC-conjugated an-
ti-HA antibody and propidium iodide. Results of FACS analysis
performed 12 h post-drug treatment were consistent with
CDC25A degradation studies and indicated that in vector-
transfected cells, 38% of untreated cells were in S phase,
whereas 85% of irofulven-treated cells were in S phase (Fig.
9, B and C). Among the CHK2.kd-transfected cells, the total
cell population presented a similar cell cycle distribution pat-
tern as vector-transfected cells after irofulven treatment. But
when cells were gated for only FITC-positive (CHK2.kd-trans-
fected) cells, after irofulven treatment, the number of cells in S
phase was decreased by 20% (Fig. 9, B and C), indicating that
introduction of kinase-dead CHK2 inhibited irofulven-induced
S phase arrest.
Taken together, it was concluded that CHK2 activation by
irofulven contributes to S phase arrest.
FIG. 7. ATM and CHK2 target proteins activated by irofulven.
A and B, human ovarian cancer cell lines A2780, CAOV3, SKOV3, and
OVCAR3 were treated with 1 IC50 concentration of irofulven (A); and
human normal fibroblast GM00637 and AT fibroblast GM05849 were
treated with 8 M of irofulven (B) for 1 h followed by additional 24 h of
incubation. Western blot analyses were performed with antibodies
against phosphorylated NBS1 on Ser343, NBS1, phosphorylated SMC1
on Ser957, SMC1, and phosphorylated p53 on Ser15. The nonspecific
band was indicated as n.s. C and D, A2780 and CAOV3 cells (C); and
human colon cancer cell line HCT116 and its CHK2 knockout subline
(D) were treated with 1 IC50 concentration of irofulven for 1 h followed
by additional 24 h of incubation, Western blots were performed with
antibodies against phosphorylated p53 on Ser20, p53, and actin.
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FIG. 8. Irofulven-induced CHK2 activation contributes to S phase arrest. A, human colon cancer cell line HCT116 and its CHK2 knockout
derivative were treated with 1 IC50 concentration of irofulven for 1 h followed by additional 12 or 24 h of incubation, CHK2 activation was
observed by Western blot with antibody recognizing the phosphorylated form of CHK2 kinase on Thr68. Western blots for CHK2 and actin served
as loading control. B and C, HCT116 CHK2/ and CHK2/ cells were pulse-labeled with 10 M of BrdU for 1 h followed by 1-h drug treatment
at 1 IC50 concentration. Untreated and treated cells were harvested at different time point and stained with FITC-conjugated anti-BrdU antibody
and propidium iodide. Cells were then applied to FACS analysis. The BrdU-positive cells were gated and histograms of DNA content versus cell
counts (30,000 events) were obtained. The percentage of each cell cycle phase was analyzed by ModFit v3.0 software. S phase percentage of
CHK2/ and CHK2/ cells with or without drug treatment at different times was shown in B. The ratio of S phase percentage of
irofulven-treated over untreated for CHK2/ and CHK2/ cells was shown in C.
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DISCUSSION
Irofulven is a novel semi-synthetic derivative of the mush-
room toxin, illudin S, which has demonstrated antitumor ac-
tivity against prostate, pancreatic, and ovarian cancer in clin-
ical trials. The mechanism of irofulven action involves several
biological processes including DNA damage, MAPK signaling,
cell cycle arrest, and caspase-dependent apoptosis. The chem-
ical structure and nature of irofulven-elicited DNA lesions are
currently unknown. By using paired cell lines proficient and
deficient for ATM, ATR or CHK2 function, and by using RNA
interference techniques and transfection of dominant-negative
CHK2, we show that irofulven induces ATM-dependent CHK2
activation leading to S phase arrest, a pathway that has pri-
marily been characterized in response to ionizing radiation-
induced DNA double strand breaks (23–29). In contrast, the
ATR and CHK1 pathway, which mainly responds to drug and
UV-induced DNA lesions (23–29), does not play an important
role in irofulven-induced DNA damage response. In addition,
we also show that ATM target proteins NBS1, SMC1, and p53
were also phosphorylated in an ATM-dependent manner upon
irofulven treatment, and p53 phosphorylation on serine 20
induced by irofulven is dependent on CHK2 status. These novel
FIG. 9. Irofulven induces CDC25A
degradation and expression of ki-
nase-dead CHK2 inhibits irofulven-
induced S phase arrest. A, ovarian can-
cer cell line CAOV3 was treated with 1
IC50 concentration of irofulven for 1 h fol-
lowed by additional 24 h incubation;
Western blots were performed with anti-
bodies against CDC25A and actin. To in-
hibit CDC25A degradation, cells were cul-
tured in the presence of the proteasome
inhibitor LLnL (50 M). LLnL was added
30 min before irofulven treatment. B,
CAOV3 cells were transfected with vector
or HA-tagged kinase-dead CHK2
(CHK2.kd) as described under “Experi-
mental Procedures.” Cells were stained
with FITC-conjugated anti-HA antibody
and propidium iodide. Cells were then ap-
plied to FACS analysis. Triplicate exper-
iments were carried out. The FITC-posi-
tive cells were gated and histograms of
DNA content versus cell counts were ob-
tained. In the vector-transfected group,
30,000 events were recorded. In the
CHK2.kd-transfected group, ten times
more events were recorded to overcome
the low transfection efficiency. C, S phase
percentage of vector and CHK2.kd-trans-
fected cells with or without irofulven
treatment.
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observations may aid in the further elucidation of the molecu-
lar mechanisms of action of irofulven, and in the potential
design of combined therapy with radiation, S phase abrogators,
or inhibitors of the ATM-CHK2 signaling pathway.
CHK2 has been shown to be involved in DNA repair process
at stalled replication forks by interacting with ATR, p53, and
BRCA1 (28, 92–94). A recent study done in fission yeast dem-
onstrated that Cds1 (CHK2) interacts with Rad60, a protein
required for recombinational repair in fission yeast. Cds1 acti-
vation triggers Rad60 phosphorylation and nuclear delocaliza-
tion regulating recombination events at stalled replication
forks (95). While it is yet to be determined whether CHK2
activation might also play a role in repairing irofulven-elicited
DNA lesions, it has been reported that irofulven-induced DNA
damage is repaired by transcription-coupled nucleotide exci-
sion repair (TC-NER) (21). Therefore, it can be speculated that
the CHK2 activation by irofulven might be the result of stalled
replication machinery. Supporting this idea, CHK2 activation
by irofulven in ovarian cancer cell lines has been found to be
replication and transcription-dependent (data not shown). In-
terestingly, it has also been reported that DNA double-
stranded breaks (DSB) are observed in irofulven-treated cells
(96). Therefore, having a better understanding of the types of
lesions formed by irofulven will help in uncovering the novel
recognition and signaling pathway evoked by this drug.
In response to IR-induced DNA damage, ATM or ATR di-
rectly phosphorylates p53, NBS1, SMC1, MDM2, and BRCA1
(23,30–37,50–53). Activation of NBS1, SMC1, and BRCA1
plays a very important role in S and G2/M checkpoint control
(22, 23, 30–41, 50–53, 66, 97, 98). Activation of SMC1 has also
been shown to contribute to radiosensitivity (33). Recent stud-
ies demonstrated that parallel pathways exist in radiation-
induced intra-S phase checkpoint. ATM phosphorylates CHK2
and NBS1, two branches of the ATM-mediated DNA damage
response pathway (ATM-CHK2-CDC25A-CDK2 and ATM-
NBS1-MRE11-RAD50), each of which partially controls intra-S
phase arrest (30, 32, 34, 65, 66, 99). We demonstrated in this
study that irofulven induces phosphorylation of NBS1 on
Ser343, SMC1 on Ser957, and p53 on Ser15 in an ATM-depend-
ent manner, and induces p53 phosphorylation on Ser20-depend-
ent on CHK2 status. The potential roles of NBS1, SMC1, and
BRCA1 in irofulven-induced DNA damage response, CHK2
activation, and chemosensitivity provide avenues for future
research.
It has been previously determined that CHK2 regulates G1
arrest by activating p53 (54–56), S phase checkpoint by phos-
phorylating CDC25A (65–67), or G2/M transition by phospho-
rylating CDC25C (42, 73, 74) following DNA damage. However,
controversy exists regarding the role of CHK2 in cell cycle
regulation. One report suggested that CHK2 is dispensable for
p53-mediated G1 arrest (77), while other studies demonstrated
that cells from CHK2 knockout mice have normal S phase and
G2/M transition (56, 57). Additionally, it has been argued that
it is unlikely CHK1 and CHK2 are regulators of p53 or the G1
and G2 checkpoints activated by IR (78, 79). Yet, CHK2 has
been shown to play a partial role in controlling the S phase
checkpoint upon IR treatment (66). In this study, we found that
CHK2 contributes to the S phase arrest induced by irofulven.
By BrdU labeling and analysis of BrdU-positive cells, S phase
delay between 9- and 12-h period in irofulven-treated, BrdU-
positive CHK2/ and CHK2/ cells was observed. An in-
crease of S phase cells was also observed in CHK2/ cells
treated with irofulven, but the number of cells arrested in S
phase in CHK2/ cells was constantly higher than in
CHK2/ cells. The magnitude of differences in S phase arrest
between irofulven-treated CHK2/ and CHK2/ cells de-
clined over the time. Because cells were treated with relatively
low (1 IC50) drug concentrations, it is possible that this is
related to the ability of viable cells to recover from drug insult.
In addition, by transfecting kinase-dead CHK2 into ovarian
cancer cells, FACS analysis results indicated that S phase
arrest induced by irofulven was inhibited.
CHK2 has also been implicated in apoptosis induction (56,
77, 85, 100–102). We have previously found that irofulven
strongly induces JNK and ERK activation and caspase-medi-
ated apoptosis in pancreatic cancer cell lines (19, 20). There
have been reports indicating that the JNK or ERK activation in
response to DNA damage might be regulated by ATM- or ATR-
initiated pathways (103–107). Therefore, the possible role of
CHK2 activation in irofulven-induced cell death and the link
between DNA-damage response and MAPK activation induced
by irofulven remain to be elucidated.
In summary, irofulven, a novel anticancer agent, activates a
DNA damage signaling pathway by triggering ATM-dependent
activation of NBS1, SMC1, CHK2 and p53 activation. The
degree of CHK2 activation is dependent on both irofulven con-
centration and length of exposure. Furthermore, it was dem-
onstrated that CHK2 activation contributes to irofulven-in-
duced S phase arrest.
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